Health AI Central
Share:
Peer-Reviewed Publication
Cell Rep2022;41(8):111704.November 22, 2022Journal Article

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors.

Laura Urbanski1, Mattia Brugiolo2, SungHee Park2, Brittany L Angarola2, Nathan K Leclair1, Marina Yurieva2, Phil Palmer3, Sangram Keshari Sahu3, Olga Anczuków4
1The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Graduate Program in Genetics and Development, UConn Health, Farmington, CT, USA.
2The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
3Lifebit, London, UK.
4The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA. Electronic address: olga.anczukow@jax.org.
PubMed PMC DOI PDF

Abstract

MYC is dysregulated in >50% of cancers, but direct targeting of MYC has been clinically unsuccessful. Targeting downstream MYC effector pathways represents an attractive alternative. MYC regulates alternative mRNA splicing, but the mechanistic links between MYC and the splicing machinery in cancer remain underexplored. Here, we identify a network of co-expressed splicing factors (SF-modules) in MY…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.